How Does Incyte Stock's Decline During The 2022 Inflation Shock Compare With The 2008 Crash?
The stock price of Incyte Incyte , a biopharmaceutical company, trades at $58 per share, about 43% below its peak level of $100 seen in January 2021. INCY stock was trading at around $76 in early J...
S&P 500 Gains and Losses Today: Incyte Stock Pops on Buyback Plan
Major U.S. equities indexes were mixed and little changed Monday to kick off a new trading week that will provide investors with a few key economic data points.
Incyte's (INCY) Q1 Earnings & Revenues Fall Shy of Estimates
Incyte's (INCY) first-quarter 2024 earnings and revenues miss estimates. The company maintains 2024 revenue guidance for its lead drug, Jakafi.
Incyte (INCY) Q1 Earnings: How Key Metrics Compare to Wall Street Estimates
While the top- and bottom-line numbers for Incyte (INCY) give a sense of how the business performed in the quarter ended March 2024, it could be worth looking at how some of its key metrics compare...
Incyte misses quarterly profit on weak sales of lead drug
Incyte Corp on Tuesday reported first-quarter profit below Wall Street estimates on weak sales of its blood cancer drug Jakafi, sending its shares down 2.4%.
Incyte (INCY) Earnings Expected to Grow: Should You Buy?
Incyte (INCY) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Why Is Incyte (INCY) Up 1.8% Since Last Earnings Report?
Incyte (INCY) reported earnings 30 days ago. What's next for the stock?
Incyte (INCY) Posts Positive Results on Opzelura From HS Study
Incyte's (INCY) Opzelura leads to a significantly greater reduction in abscess and inflammatory nodule (AN) count in HS patients.
Penny Stock Detox: 3 Stocks to Buy for Multibagger Returns Instead
The allure of penny stocks is understandable. For literally just a few dollars, you can control hundreds, if not thousands, of shares.
Exit Now! 3 Biotech Stocks to Sell in February 2024
The unpredictability of the biotech sector, highlights the inherent risks involved in certain biotech stocks to sell. 2023 was a rough year for the market, marked by a 10% plunge in the SPDR S&P Bi...
Incyte's (INCY) Q4 Earnings & Revenues Fall Shy of Estimates
Incyte's (INCY) fourth-quarter 2023 earnings and revenues miss estimates. Quarterly revenues cross the $1 billion mark for the first time on the continued growth of Jakafi and the strong launch of ...
Incyte Corporation (INCY) Q4 2023 Earnings Call Transcript
Incyte Corporation (INCY) Q4 2023 Earnings Call Transcript
Here's What Key Metrics Tell Us About Incyte (INCY) Q4 Earnings
The headline numbers for Incyte (INCY) give insight into how the company performed in the quarter ended December 2023, but it may be worthwhile to compare some of its key metrics to Wall Street est...
Ahead of Incyte (INCY) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
Evaluate the expected performance of Incyte (INCY) for the quarter ended December 2023, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metri...
Incyte (INCY) Banks on Opzelura as Jakafi Faces Competition
Incyte (INCY) is likely to rebound in 2024 on the solid growth of Opzelura and additional label expansions.
Related Companies